MEDIX, God. 23 Br. 126  •  Sponzorirani članak  •  Kardiologija HR ENG

Rivaroksaban u kliničkoj praksi za prevenciju moždanog udara u bolesnika s nevalvularnom fibrilacijom atrijaRivaroxaban in clinical practice for stroke prevention in patients with non-valvular atrial fibrillation

Aleksandar Knežević

Randomizirana kontrolirana klinička ispitivanja smatraju se zlatnim standardom istraživačkoga rada u kliničkoj medicini, no rezultati tih ispitivanja ne odražavaju uvijek kompleksnost svakodnevnoga liječenja. Stoga se sve više provode istraživanja iz kliničke prakse, koja bolje oslikavaju „realan život“. Što se tiče rivaroksabana, u XANTUS prospektivnom neintervencijskom praćenju potvrđeni su učinkovitost i povoljan sigurnosni profil rivaroksabana u bolesnika s nevalvularnom fibrilacijom atrija (FA), što je prvotno utvrđeno u ROCKET AF registracijskom istraživanju. Rezultati retrospektivnih analiza baza podataka (američka REVISIT-US, njemačka RELIEF), potom US Department of Defense Postmarketing Safety Surveillance Study (US DoD PMSS) i danskih registara, dodatno podupiru te nalaze i daju komplementarne podatke o postregistracijskoj uporabi rivaroksabana u svakodnevnoj praksi. Međunarodni i lokalni registri, kao što su: GARFIELD-AF, ORBIT-AF i Dresden NOAK registar, upućuju na sve veću primjenu NOAK-a u odnosu na antagoniste vitamina K te na činjenicu da je rivaroksaban valjana antikoagulacijska opcija za primjenu u bolesnika s nevalvularnim FA-om u svakodnevnoj praksi.

Ključne riječi:
fibrilacija atrija; klinička praksa; prevencija moždanog udara; rivaroksaban

Članak u cijelosti pročitajte u tiskanom izdanju MEDIX, God. 23 Br. 126

Randomised controlled clinical trials are considered the gold standard of research in clinical medicine, but the results of these trials do not always reflect the complexity of everyday treatment. Therefore, a research from clinical practice is being carried out increasingly, better illustrating „real-life“. When it comes to rivaroxaban, a prospective noninterventional observational study XANTUS has confirmed efficacy and favorable safety profile of rivaroxaban in patients with non-valvular atrial fibrillation (AF), as had previously been established in ROCKET AF registration study. The results from retrospective database analyses (American REVISIT-US, German RELIEF), US Department of Defense Postmarketing Safety Surveillance Study (PMSS) as well as from the Danish registries, additionally support these findings and provide complementary data on post-registration use of rivaroxaban in everyday practice. International and local registers, such as GARFIELD-AF, ORBIT-AF and Dresden NOAC registry, indicate an increasing administration of NOAC compared to vitamin K antagonists and the fact that rivaroxaban is a valid anticoagulant option for the use in daily practice in patients with non-valvular AF.

Key words:
atrial fibrillation; clinical practice; rivaroxaban; stroke prevention